China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions has entered into a strategic partnership with fellow Chinese firm Dragon Sail Pharmaceutical (Shanghai) Co., Ltd. This collaboration aims to focus on the research and development (R&D), manufacturing, and supply chain of antibody drug conjugates (ADCs), with no financial terms disclosed.
Combining Expertise in CDMO and Biological Drug Development
Porton Pharma Solutions, a leading end-to-end integrated CDMO company, is recognized for its globally advanced technology platforms and extensive project delivery experience across various therapeutic areas, including small molecules, peptides, oligonucleotides, and ADCs. This encompasses the entire spectrum from antibodies and payload-linkers to conjugation and drug product filling. Dragon Sail Pharmaceutical brings its unique strengths in the development of biological drugs, such as monoclonal antibodies, bispecific antibodies, and fusion proteins, to the table.
Joint Efforts to Streamline ADC Drug Development
By integrating their R&D resources, technical expertise, and production capabilities, Porton Pharma Solutions and Dragon Sail Pharmaceutical will establish a close cooperation mechanism. This will involve sharing supply chain resources and leveraging complementary advantages to build a one-stop service cooperation platform for ADC drugs. The platform will cover everything from raw materials to formulations and from early R&D to commercial production.
Enhancing Efficiency and Market Competitiveness
The partnership’s goal is to reduce the development timelines for ADC drugs, bolster service and delivery capabilities, and increase market competitiveness. This collaboration aims to provide global customers with more efficient and reliable one-stop CMC solutions for ADC drugs, thereby enhancing the overall service offering in the rapidly evolving field of antibody drug conjugates.-Fineline Info & Tech
